Browse the evidence

GLP-1 receptor agonists (GLP-1 RAs) can lead to modest yet statistically significant reductions in systolic blood pressure (SBP).

GLP-1 RAs may be considered as adjunctive therapies for managing hypertension.

Recent innovations in bariatric research include pharmacological therapies targeting GLP-1 receptors, minimally invasive procedures, and genetic and microbiome-based strategies.

These innovations may provide new options for obesity treatment.

Among 1,059,605 Veterans with incident prediabetes, 12,009 (1.1%) were prescribed metformin during an average 3.4 years of observation after diagnosis.

Practitioners should note that metformin is prescribed to a small percentage of Veterans with prediabetes.

Over 20% of Veterans with prediabetes attended a comprehensive structured lifestyle modification clinic or program.

Practitioners should encourage participation in lifestyle modification programs for Veterans with prediabetes.

Gastrointestinal adverse events were recorded in most studies but did not impact overall weight loss.

Practitioners should be aware of potential GI side effects but can consider semaglutide effective for weight loss despite these events.

Intensive glycemic control can precipitate hypoglycemic events, which may lead to serious complications.

Healthcare providers should monitor patients closely to prevent hypoglycemic events during intensive glycemic control.

Recommendations for collaborative action include developing obesity education and care standards that incorporate patients' perspectives.

Healthcare systems should prioritize patient-centered approaches in obesity care.

Obesity increases the risk of hypertension and other cardiometabolic comorbidities.

Practitioners should be aware of the increased risk of hypertension in obese patients.

Surgical treatment of obesity is more effective in treating obesity-associated diseases than conservative treatment.

Surgical options may be prioritized for patients with obesity-related health issues.

Metabolic disorders such as obesity, type 2 diabetes, and dyslipidaemia are major drivers of cardiovascular risk.

Practitioners should focus on addressing metabolic disorders to reduce cardiovascular risk.

Emerging therapies for genetic and syndromic obesities include approved treatments like setmelanotide and semaglutide.

Practitioners should consider the use of approved therapies like setmelanotide and semaglutide in treatment plans.

New pharmacological approaches aim to conserve lean body mass during weight loss.

Emerging drugs may help maintain muscle mass during weight loss, which is crucial for long-term success.

Patients with obesity are at increased risk for developing type 2 diabetes, heart attack, stroke, liver disease, and obstructive sleep apnea.

Healthcare providers should monitor and address these risks in patients with obesity.

GLP-1 receptor agonists are approved for steatotic liver disease, with demonstrated histologic and biochemical benefits.

GLP-1 receptor agonists can be utilized in clinical practice for managing steatotic liver disease effectively.

The treatment adherence rate was 84.6%, with 170 out of 201 patients completing the therapy.

High adherence suggests that the therapy is well-received by patients.

Weight re-gain is a common concern after bariatric procedures.

Clinicians should prepare patients for the possibility of weight re-gain and consider revisional surgery options.

The evolution of anti-obesity pharmacotherapy has progressed to modern gut hormone-based therapies, notably glucagon-like peptide-1 receptor agonists (GLP-1RAs), which effectively suppress appetite and improve glycemic control.

Practitioners should consider GLP-1RAs as effective options for appetite control and glycemic management in obesity treatment.

Among 11,700 reports from July 2009 to April 2024, 13 incidents related to GLP-1 agonist use were identified, including seven cases concerning aspiration.

Clinicians should be aware of the potential aspiration risks associated with GLP-1 agonist use in the perioperative setting.

Exenatide combined with Metformin improved 2-hour oral glucose tolerance test (OGTT) values by a mean difference of -1.78 (p < 0.001).

The combination therapy may enhance glucose tolerance in women with PCOS.

HbA1c decreased from 5.5 ± 0.3 at baseline to 5.3 ± 0.3 at 12 weeks and to 5.2 ± 0.027 at 24 weeks.

Practitioners can expect improvements in glycemic control in patients using compounded GLP-1 ± GIP agonists.

Multiple incretin pharmaceutical agents show promise in the prevention and treatment of T2D.

Stay informed about new incretin agents for T2D prevention and treatment.

Ingestion of a single bolus of hydrolyzed collagen or free amino acids substantially increases circulating amino acids concentrations, particularly glycine.

Practitioners can consider collagen and amino acid supplementation to enhance amino acid availability post-exercise.

There were no differences in lean body mass gains between the peanut-based and high-carbohydrate snack groups.

Both snack types may be equally effective for increasing lean body mass in athletes.

The prevalence of low energy availability (LEA) in female collegiate beach volleyball athletes was 30.8% in the preseason, 37.5% at week 1, 25.0% at week 5, and 62.5% at week 9.

Coaches and nutritionists should monitor energy availability closely throughout the competitive season.